Sendai virus, a candidate vaccine for the prevention of respiratory virus infections in children: a review

Background Respiratory viruses including human parainfluenza virus (hPIV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV), pose serious, potentially lethal threats to humans, particularly infants and young children. While maternal vaccines and monoclonal antibodies are advancing to provide transient protection against these viruses, licensed pediatric vaccines are not yet available. Sendai virus (SeV) is now being developed as an intranasal (I.N.) vaccine candidate for the prevention of serious respiratory viral infections in children. Methods To examine the potential of replication-competent Sendai virus and its recombinants as pediatric respiratory virus vaccines against hPIV, RSV and hMPV, we searched literature databases and evaluated both historical and contemporary published research. Results SeV and SeV recombinant vaccines have been tested pre-clinically in a variety of animal models and in Phase I clinical studies. In pre-clinical models, a single dose of SeV induced rapid and long-lasting B- and T-cell responses in the upper respiratory tract and blood. When recombinant SeV constructs were produced and formulated into cocktail vaccines, they were protective against four different respiratory pathogens simultaneously. Vaccines were successful when partnered with passively transferred antibodies; specifically, when a recombinant SeV-based RSV vaccine was tested in the presence of passively transferred monoclonal or polyclonal PIV-specific or RSV-specific antibodies in a cotton rat model, the vaccine provided durable protective immunity against RSV. In clinical trials, SeV was well-tolerated and uniformly immunogenic in PIV-seropositive 1–2 year old children. Methods have been developed for the manufacture of stable SeV-based vaccine products, compatible with wide global distribution of SeV vaccines for clinical use. Conclusion To date, results highlight SeV as an attractive pediatric vaccine candidate. Continued clinical testing of SeV may provide global relief from serious respiratory viral infections in infants and young children.

Authors

Institutions

Publication Details

Journal
Frontiers in Microbiology
Published
2026-11-16
DOI
https://doi.org/10.3389/fmicb.2026.2002178
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sendai virus, a candidate vaccine for the prevention of respiratory virus infections in children: a review

Sherri L. Surman, Octavio Ramilo, Toru Takimoto, Elisabeth E. Adderson et al.
1 links
Frontiers in Microbiology
Respiratory viral infections research
article

Sendai virus, a candidate vaccine for the prevention of respiratory virus infections in children: a review

Sherri L. Surman, Octavio Ramilo, Toru Takimoto, Elisabeth E. Adderson, David I. Bernstein, Bart G. Jones, Christopher Coleclough, Karen S. Slobod, Julia L. Hurwitz, Leena Yeolekar, Rajeev Dhere, Kim J. Allison, Kristen Branum
article en

Abstract

Background Respiratory viruses including human parainfluenza virus (hPIV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV), pose serious, potentially lethal threats to humans, particularly infants and young children. While maternal vaccines and monoclonal antibodies are advancing to provide transient protection against these viruses, licensed pediatric vaccines are not yet available. Sendai virus (SeV) is now being developed as an intranasal (I.N.) vaccine candidate for the prevention of serious respiratory viral infections in children. Methods To examine the potential of replication-competent Sendai virus and its recombinants as pediatric respiratory virus vaccines against hPIV, RSV and hMPV, we searched literature databases and evaluated both historical and contemporary published research. Results SeV and SeV recombinant vaccines have been tested pre-clinically in a variety of animal models and in Phase I clinical studies. In pre-clinical models, a single dose of SeV induced rapid and long-lasting B- and T-cell responses in the upper respiratory tract and blood. When recombinant SeV constructs were produced and formulated into cocktail vaccines, they were protective against four different respiratory pathogens simultaneously. Vaccines were successful when partnered with passively transferred antibodies; specifically, when a recombinant SeV-based RSV vaccine was tested in the presence of passively transferred monoclonal or polyclonal PIV-specific or RSV-specific antibodies in a cotton rat model, the vaccine provided durable protective immunity against RSV. In clinical trials, SeV was well-tolerated and uniformly immunogenic in PIV-seropositive 1–2 year old children. Methods have been developed for the manufacture of stable SeV-based vaccine products, compatible with wide global distribution of SeV vaccines for clinical use. Conclusion To date, results highlight SeV as an attractive pediatric vaccine candidate. Continued clinical testing of SeV may provide global relief from serious respiratory viral infections in infants and young children.

Frontiers in MicrobiologyVol. 17
Cincinnati Children's Hospital Medical Center (US), St. Jude Children's Research Hospital (US), University of Rochester Medical Center (US), Serum Institute of India (India) (IN), University of Rochester (US)
Good health and well-being
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon